|drug1568||Lianhua Qingwen Wiki||1.00|
|D045169||Severe Acute Respiratory Syndrome NIH||0.05|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The acute lung injury caused by SARS and 2003 were both related to the inflammatory cytokine storm in patients. The biochemical test showed abnormal increase in related indicators such as interleukin-8, and CT images showed a medical "white" lung". According to the experience of SARS treatment in 2003, the use of hormones will indeed help the patients to alleviate their illness, but patients who survived SARS either had too much hormone at that time and took too long. Although the lungs could recover, but the femoral head was necrotic Either the amount of hormones was very conservative at the time, which kept the lungs in the storm of inflammatory factors, leading to the emergence of irreversible pulmonary fibrosis. So is there a medicine that can anti-inflammatory, reduce the load of hormone use, and have the effect of treating and preventing pulmonary fibrosis complicated by severe viral lung? At present, pirfenidone has achieved encouraging results in the treatment of idiopathic Pulmonary Fibrosis (CTD-ILD) diseases. It is particularly encouraging that the values announced at the 2019 ATS Annual Conference suggest that pirfenidone has more anti-inflammatory and anti-oxidant effects than its own outstanding anti-fibrotic ability. The data shows early use, Its strong anti-SOD activity can effectively inhibit IL-1beta and IL-4, and can open the prevention mode of pulmonary interstitial fibrosis. Based on the above, this project intends to make the following scientific assumptions: based on the homology of the pathogens of the new coronavirus-infected pneumonia and the coronavirus infection of pneumonia in 2003, the similarities in the occurrence and development of the disease, that is, the pulmonary inflammatory storm occurs first, and thereafter The progress of fibrosis and the progressive decline of lung function and mortality are higher than those of ordinary pneumonia. We hope that by adding pirfenidone as a treatment program in addition to standard treatment, it will be a new and severe type of coronavirus infection. Patient clinical treatment provides an effective and practical method.
Description: Lesion area of chest CT image at 4 weeksMeasure: chest CT Time: 4 weeks
Description: Absolute change in pulse oxygen from baselineMeasure: Finger pulse oxygen Time: 4 weeks
Description: Absolute change in blood gas from baselineMeasure: blood gas Time: 4 weeks
Description: Absolute change in total score of King's brief questionnaire for interstitial Absolute change in total score of King's brief questionnaire for interstitial pulmonary disease (k-bild) from baseline at week 4Measure: K-BILD Time: 4 weeks
Description: Time to death within 4 weeks due to respiratory problemsMeasure: death Time: 4 weeks
Description: Time to disease progression or death within 4 weeksMeasure: Time to disease progression or death within 4 weeks Time: 4 weeks
Description: lymphocyte countMeasure: blood Time: 4 weeks
Description: Absolute change in viral nucleic acid from baselineMeasure: viral nucleic acid Time: 4 weeks
Description: Pulmonary fibrosis survival symptoms absolute changes in dyspnea score from baselineMeasure: dyspnea score Time: 4 weeks
Description: changes in blood inflammatory indexesMeasure: blood Time: 4 weeks
Description: Absolute change in cough scores for pulmonary fibrosis survival symptoms from baselineMeasure: cough scores Time: 4 weeks